SRSF7 and neoplasm: By targeting tumor cells and the C1 SRSF7+ MCs subtype for interactions analysis, we have identified the secretion of AREG ligands by a subtype of C1 SRSF7+ MCs in the EGF signaling pathway that act on the protein receptor EGFR on the membrane of the tumor cells.